AHA 2018 Late Breakers: New Cholesterol Guidelines Lead Exciting Science from AHA 2018

Here are several late-breaking trials from DocWire News’ coverage of the American Heart Association’s 2018 Scientific Sessions in Chicago. New cholesterol guidelines making some important adjustments led the news, along with the full results for the REDUCE-IT study, and much more important science that impacts practice. Stay tuned to DocWire News for exclusive video interviews with trial presenters and others. 

 

Individualized Risk Assessment, New LDL-lowering Options Among Highlights in 2018 AHA/ACC Cholesterol Guidelines 

Personalized risk assessments and new cholesterol-lowering therapies were among the new key recommendation of the American Heart Association/American College of Cardiology 2018 Cholesterol Guidelines, presented at the American Heart Association 2018 Scientific Sessions in Chicago. 

Read more at DocWire News. 

 

PIONEER-HF: Sacubitril-Valsartan Stabilizes Acute Decompensated HF, Reduces Rehospitalization 

In patients with hemodynamically stabilized acute heart failure with reduced ejection fraction (HFrEF), a combination therapy of sacubitril-valsartan therapy led to greater reductions in NT-proBNP concentration compared to enalapril therapy, according to new trial results presented at the American Heart Association 2018 Scientific Sessions. 

Read more at DocWire News. 

 

REDUCE-IT: Icosapent Ethyl Reduces Significantly Reduces CV Events in Statin-treated Patients 

In patients on statin therapy with established cardiovascular disease (CVD) who also have elevated cholesterol and triglycerides, icosapent ethyl was associated with a 25% reduction in risk for cardiovascular events, according to the full results of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) presented at the American Heart Association 2018 Scientific Sessions in Chicago.  

Read more at DocWire News. 

 

DECLARE-TIMI 58: Dapagliflozin Safe, Reduced CV Death in Patients with Type 2 Diabetes Mellitus 

Dapagliflozin neither increased nor decreased major adverse cardiovascular events (MACE), but did reduce other adverse outcomes, new study results presented at the American Heart Association 2018 Scientific Sessions. 

Read more at DocWire News. 

 

TiCAB: No Additional Benefit from Ticagrelor Monotherapy vs. Aspirin in CABG Patients 

Ticagrelor monotherapy did not yield an additional benefit for cardiovascular events or in terms of bleeding compared to aspirin monotherapy in patients undergoing coronary artery bypass graft (CABG), new study results presented at the American Heart Association 2018 Scientific Sessions suggested.  

Read more at DocWire News.